1197159-91-3

Basic information

• Product Name: 4-(4,6-dimorpholino-1,3,5-triazin-2-yl)aniline
• Synonyms: 4-(4,6-dimorpholino-1,3,5-triazin-2-yl)aniline;4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)benzenamine;EOS-60915
• CAS NO: 1197159-91-3
• Molecular Formula: C₁₇H₂₂N₆O₂
• Molecular Weight: 342.39558
• EINECS: -0
• Mol File: 1197159-91-3.mol
• Article Data: 16

Chemical Properties

• Melting Point: 266 °C
• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 4-(4,6-dimorpholino-1,3,5-triazin-2-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4,6-dimorpholino-1,3,5-triazin-2-yl)aniline(1197159-91-3)
• EPA Substance Registry System: 4-(4,6-dimorpholino-1,3,5-triazin-2-yl)aniline(1197159-91-3)

Safety Data

• Hazardous Substances Data: 1197159-91-3(Hazardous Substances Data)

Usage

General Description

4-(4,6-dimorpholino-1,3,5-triazin-2-yl)aniline is a chemical compound that belongs to the class of anilines, which are organic compounds consisting of a benzene ring with an amino group attached at the position. This specific compound also contains a triazine ring and two morpholino groups. It is commonly used in the synthesis of pharmaceuticals, dyes, and other organic compounds. It has potential applications in medicinal chemistry due to its structural features and ability to participate in various chemical reactions. Additionally, it may have uses in the development of new materials or as a reagent in organic synthesis. However, the compound should be handled with care and precautions as with any chemical due to its potential hazards and toxic properties.

Upstream product

• 7597-22-0 2-chloro-4,6-di-morpholin-4-yl-[1,3,5]triazine 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 89415-43-0 (4-aminophenyl)boronic acid 
• 330793-01-6 (4-tert-butoxycarbonylaminophenyl)boronic acid pinacol ester 
• 619-72-7 4-nitrobenzonitrile 
• 29366-73-2 2,4-diamino-6-(4-nitrophenyl)-1,3,5-triazine 
• 6601-22-5 2,6-Dichloro-4-morpholino-1,3,5-triazine 

Downstream Products

• 1197159-90-2 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-4-ylurea 
• 1197159-93-5 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-phenylurea 
• 1197160-00-1 (2,4-difluorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea 
• 1197160-01-2 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-ethylurea 
• 1197159-96-8 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-fluorophenyl)urea 
• 1197159-98-0 1-(4-chlorophenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea 
• 1197159-95-7 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-(4-methylphenyl)urea 
• 1197159-92-4 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-pyridin-3-ylurea 
• 1197159-94-6 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-thiophen-2-ylurea 
• 1197165-55-1 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-methylurea 
• 1197160-55-6 methyl 4-({[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]carbamoyl}amino)benzoate 
• 1197160-49-8 1-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]-3-[4-(1-hydroxyethyl)phenyl]urea 

Relevant articles and documents

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class i PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe the preclinical characterization of compound 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concentrations. No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays. Moreover, 1 did not bind tubulin, which was observed for the structurally related 4 (BKM120, buparlisib). Compound 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs. Compound 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model. This, together with the compound's safety profile, identifies 1 as a clinical candidate with a broad application range in oncology, including treatment of brain tumors or CNS metastasis. Compound 1 is currently in phase II clinical trials for advanced solid tumors and refractory lymphoma.

Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer

The development of inhibitors targeting the PI3K-Akt-mTOR signaling pathway has been greatly hindered by the on-target AEs, such as hyperglycemia and hepatotoxicities. In this study, a series of diaryl urea derivatives has been designed and synthesized based on clinical candidate gedatolisib (6aa), and most of the newly synthesized derivatives showed kinase inhibitory and antiproliferative activities within nanomolar and submicromolar level, respectively. The terminal l-prolineamide substituted derivative 6 ab showed 8.6-fold more potent PI3Kα inhibitory activity (0.7 nM) and 4.6-fold more potent antiproliferative effect against HCT116 cell lines (0.11 μM) compared with control 6aa. The potential antitumor mechanism and efficacy of 6 ab in HCT116 xenograft models have also been evaluated, and found 6 ab showed comparable in vivo antitumor activity with 6aa. The safety investigations revealed that compound 6 ab exhibited more safer profiles in the selectivity of liver cells (selectivity index: >6.6 vs 1.85) and blood glucose regulation than 6aa. In addition, the in vitro stability assays also indicated our developed compound 6 ab possessed good metabolic stabilities.

HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF

Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

PI3Kalpha/mTOR bikinase inhibitor as well as pharmaceutical composition and application thereof

The invention discloses a PI3Kalpha/mTOR bikinase inhibitor as well as a pharmaceutical composition and application thereof. The PI3Kalpha/mTOR bikinase inhibitor is prepared from a compound shown ina general formula (I), or a stereoisomer, a geometric isomeride, a hydrate, a solvate, or pharmaceutically acceptable salt or a prodrug: (the formula (1) is shown in the description.) The invention provides the PI3Kalpha/mTOR bikinase inhibitor and the pharmaceutical composition thereof for inhibiting PI3Kalpha/mTOR bikinase and proliferation diseases having a PI3Kalpha/mTOR bikinase effect; moreover, a more effective and higher selectivity inhibitor can be provided for treating the proliferation diseases having the PI3Kalpha/mTOR bikinase effect.